STOCK TITAN

Paratek Pharmaceuticals Inc. - PRTK STOCK NEWS

Welcome to our dedicated news page for Paratek Pharmaceuticals (Ticker: PRTK), a resource for investors and traders seeking the latest updates and insights on Paratek Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Paratek Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Paratek Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.21%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
none
Paratek Pharmaceuticals Inc.

Nasdaq:PRTK

PRTK Rankings

PRTK Stock Data

127.83M
50.11M
11.7%
55.08%
4.6%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About PRTK

paratek pharmaceuticals (nasdaq: prtk) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. we focus on drugs that target infectious disease and other difficult to treat conditions. our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against gram-positive, gram-negative and atypical bacteria. omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. the food and drug administration (fda) granted omadacycline a qualified infectious disease product (qidp) designation and completed two special protocol assessments for its phase 3 clinical trial program.